

Mouse Anti-Amyloid Beta 1-40 [20.1]: MC0596, MC0596RTU7

Intended Use: For Research Use Only

Description: The Proteolytic cleavage of the amyloid protein precursor (APP) gives rise to the β -Amyloid and Amyloid A4 proteins, which are present in human platelets. Amyloid deposition is associated with type II diabetes, Down syndrome and a variety of neurological disorders, including Alzheimer's disease. The amyloid precursor protein (APP) undergoes alternative splicing, resulting in several isoforms. Proteolytic cleavage of APP leads to the formation of the 4 kDa β -Amyloid/A4 protein. This protein is involved in the formation of neurofibrillary tangles and plaques that characterize the senile plaques of Alzheimer's patients. APLP1 (amyloid precursor-like protein 1) and APLP2 are structurally similar to APP. Human APLP2 is a membrane-bound sperm protein that contains a region highly homologous to the transmembrane-cytoplasmic domains of APP found in brain plaques of Alzheimer's disease patients.


Specifications:

Clone: 20.1
Source: Mouse
Isotype: IgG2b
Reactivity: Human
Localization: Cytoplasm
Formulation: Antibody in PBS pH7.2, containing < 0.2% BSA and < 0.09% sodium azide (NaN₃)
Storage: Store at 2°- 8°C
Applications: IHC, IF, IP, WB
Package:

| Description | Catalog No. | Size |
|--------------------------------|-------------|------|
| Amyloid Beta 1-40 Concentrated | MC0596 | 1 ml |
| Amyloid Beta 1-40 Prediluted | MC0596RTU7 | 7 ml |

IHC Procedure*:

Positive Control Tissue: Brain tissue
Concentrated Dilution: 50-250
Pretreatment: Citrate pH6.0 or EDTA pH8.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C
Incubation Time and Temp: 30-60 minutes @ RT
Detection: Refer to the detection system manual
* Result should be confirmed by an established diagnostic procedure.



FFPE human brain stained with anti-Amyloid Beta using DAB

References:

1. APP controls the formation of PI(3,5)P2 vesicles through its binding of the PIKfyve complex. Currinn, H. et al. Cellular and molecular life sciences : CMLS. 73: 393-408, 2016.
2. New assay for old markers-plasma beta amyloid of mild cognitive impairment and Alzheimer's disease. Chiu, MJ. et al. Curr Alzheimer Res. 9: 1142-1148, 2012.
3. Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer's disease in vitro. Yang, CC. et al. ACS chemical neuroscience. 2: 500-5, 2011.
4. Linear epitope mapping by native mass spectrometry. Lu, X. et al. Anal. Biochem.. 395: 100-107, 2009.

Doc. 100-MC0596
Rev. A